A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Clinical trial NCT05799287 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05799287
Sponsor: RemeGen Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Primary IgA Nephropathy

Start date: 2023-04-28
Primary completion: 2026-06-01
Enrollment: 318

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.